Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases
- 650 Downloads
Melanoma patients with a high risk of recurrence may benefit from immunotherapy with mRNA-electroporated autologous monocyte-derived dendritic cells (DCs). Further benefit may be found in combining DC-therapy with interferon alfa-2b.
Patients and methods
The long-term clinical outcome of AJCC stage III/IV melanoma patients who had no evidence of disease at the time of treatment with autologous mRNA-electroporated DCs in a single-center pilot clinical trial was analyzed. Antigen loading was accomplished by co-electroporation of mRNA encoding a fusion protein between MAGE-A1, -A3, -C2, Tyrosinase, MelanA/MART-1, or gp100, and an HLA class II-targeting sequence. DCs were administered by 4–6 bi-weekly intradermal injections. IFN-α-2b (5 MIU TIW) was initiated either at recurrence (cohort 1), concomitant with DCs (cohorts 2 and 3), or following the fourth DC administration (cohort 4).
Thirty melanoma patients were recruited between April 2006 and June 2009. DC-related adverse events included grade 2 local injection site reactions in all patients, grade 2 fever and flu-like symptoms in one patient, and skin depigmentation in seven patients. After a median follow-up of over 6 years, the median relapse-free survival is 22 months (95 % CI 12–32 months). Twelve patients have died. The median overall survival has not been reached; the 2-year and 4-year survival rates are 93 and 70 %, respectively.
Adjuvant therapy following the resection of melanoma metastases with autologous mRNA-electroporated DCs, combined with interferon alfa-2b, is tolerable and results in encouraging long-term overall survival rates justifying further evaluation in a randomized clinical trial.
KeywordsDendritic cell Interferon alpha-2b mRNA Immunotherapy Melanoma
American Joint Committee on Cancer
Constitutively active Toll-like receptor 4
Cytotoxic T-lymphocyte-associated antigen 4
Granulocyte/macrophage colony-stimulating factor
Human leucocyte antigen
Mitogen-activated protein kinase
Million international units
Magnetic resonance imaging
Messenger ribonucleic acid
Positron emission tomography–computed tomography
Skin infiltrating lymphocytes
T helper type 1
Three times in a week
World Health Organization Performance Status
- 10.Eggermont AM, Chiarion-Sileni V, Grob JJ et al (2014) Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Meeting Abstracts, Alexandria 32Google Scholar
- 22.Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L (2009) Immunogenicity and antitumor effects of vaccination with peptide vaccine ± granulocyte–monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 15:1443–1451CrossRefPubMedCentralPubMedGoogle Scholar
- 27.Neyns B, Corthals J, De Greve J, De Greef C, Coulie PG, Thielemans K (2006) A cohort pilot study on therapeutic vaccination of advanced melanoma patients with dendritic cells loaded with multiple peptides or electroporated with mRNA. ASCO Meeting Abstracts 24: 18011Google Scholar
- 28.Neyns B, Corthals J, Thielemans K (2007) Interferon alfa-2b treatment following therapeutic vaccination with mRNA electroporated dendritic cells results in skin depigmentation and tumor regression in patients with advanced melanoma. ASCO Meeting Abstracts 25: 8537Google Scholar
- 32.Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2012) Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 377:23–36CrossRefPubMedGoogle Scholar
- 34.Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2013) Characterization of CD8(+) T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC–MEL). Biomed Res Int 2013:976383CrossRefPubMedCentralPubMedGoogle Scholar
- 38.Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A (2012) Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61:1033–1043CrossRefPubMedGoogle Scholar